Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Ocugen Stock Skyrocketed Today

By Joe Tenebruso - Apr 22, 2021 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts are growing more optimistic about the coronavirus vaccine maker's growth prospects.

What happened

Shares of Ocugen (OCGN 5.97%) soared 43% on Thursday following positive clinical trial results and bullish analyst commentary. 

So what

Roth Capital analyst Zegbeh Jallah reiterated his buy rating and $10 price forecast for Ocugen's stock on Wednesday after its development partner, Bharat Biotech, shared positive data from an interim analysis of a phase 3 study of Covaxin, an investigational coronavirus vaccine. 

An upwardly sloping stock chart with its reflection.

Ocugen's stock price rose sharply on Thursday. Image source: Getty Images.

Covaxin demonstrated overall efficacy of 78% against COVID-19 and 100% protection against severe forms of the disease. The vaccine candidate was also shown to have efficacy of 70% against asymptomatic cases, which Jallah said could help to combat the spread of the virus by people who show no symptoms and might not be aware that they're infected.

Now what 

Based on these results, Jallah said Ocugen could soon apply for an emergency use authorization (EUA) from the Food and Drug Administration (FDA). Ocugen's deal with Bharat Biotech stipulates that it will receive 45% of any profits the vaccine earns in the U.S. market. Thus, Jallah posits that if Covaxin is authorized for sale in the U.S., Ocugen could enjoy a "significant revenue-generating opportunity." 

Judging by today's gains, many investors apparently agree with Jallah's positive outlook for Ocugen.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.84 (5.97%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.